Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation -

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Information type: Randomised controlled trials
Source: New England Journal of Medicine
Specialities: Cancers
Summary
RCT (n=431) found PARP inhibitor talazoparib given as monotherapy was linked to improved progression-free survival vs. standard chemotherapy (8.6 vs. 5.6 months; HR disease progression /death= 0.54; 95% CI, 0.41-0.71; p<0.001). Patient-reported outcomes favoured talazoparib.
UKMi comment

Talazoparib was filed for approval in EU in June 2018 for the second or third line treatment of BRAC mutation-positive advanced breast cancer.
Related links: